ClinicalTrials.gg
CompletedNCT07871617Updated Oct 13, 2026

Prophylactic TAP Block in Laparoscopic Cholecystectomy

An interventional study of Analgesic and Analgesic transversus abdominal plane blockade (Bupivacaine) in Cholecystitis, sponsored by Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo. Completed at 1 site in Mexico. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Aug 2025, registered Oct 2026).
Updated Oct 13, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Laparoscopic cholecystectomy is the gold standard for cholelithiasis, yet postoperative pain remains a clinical challenge. Ultrasound-guided transversus abdominis plane (TAP) block has been proposed as an effective analgesic strategy. The objective of this study is to evaluate the effectiveness of prophylactic bilateral TAP block in patients undergoing elective laparoscopic cholecystectomy.

Read the detailed description

A prospective, randomized clinical trial was conducted at the "Dr. Salvador Zubirán Anchondo" General Hospital in Chihuahua, where adult patients scheduled for elective laparoscopic cholecystectomy were included. The intervention group received an ultrasound-guided bilateral TAP block prior to incision, while the control group received conventional analgesic management. Pain intensity was assessed using the Numerical Rating Scale (NRS) at 2, 6, 12, and 24 hours postoperatively; opioid consumption and adverse events were also recorded.

02

Conditions studied

  • Cholecystitis

Keywords

  • Anesthesia, local
  • cholecystectomy, laparoscopic
  • Analgesia
  • Postoperative pain
03

In context

Cholecystitis

272 studies on the registry are indexed under Cholecystitis; 46 are open to participants now.

This study's enrollment of 60 is below the median of 87 across 172 interventional studies indexed under Cholecystitis.

Browse Cholecystitis studies →

Lead sponsor

Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both genders
  • 18 years and older
  • ASA I-II
  • Programmed for a laparoscopic cholecystectomy
  • Who agree to participate

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years old
  • ASA III-IV
  • Known allergy to local anesthetics
  • Infection at the site for blockade
  • Inability to communicate pain
  • Known history of coagulopathy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Control group

    Usual pain management

    Drug: Analgesic

  • Experimental
    Experimental group

    Ultrasound-guided bilateral TAP block prior to incision

    Procedure: Analgesic transversus abdominal plane blockade (Bupivacaine)

Interventions

  • DrugAnalgesic

    Administration of any analgesic medication (e.g. paracetamol, diclofenac, etc.)

  • ProcedureAnalgesic transversus abdominal plane blockade (Bupivacaine)

    Ultrasound-guided bilateral TAP blockade before incision.

06

What researchers measure

Primary outcomes

  1. Post-operative abdominal pain

    Discomfort or nociceptive signaling originating in the abdominal wall that occurs as a direct consequence of the surgical procedure. Pain intensity was assessed using the Numerical Rating Scale (NRS) at predefined postoperative intervals (2, 6, 12, and 24 hours).

    Time frame: From the end of the surgical procedure and for up to 24 hours

Secondary outcomes

  1. Opioid consumption

    The cumulative amount of opioid medication the patient takes during a specific recovery timeframe following the surgical procedure

    Time frame: From the end of the surgical procedure and for up to 24 hours

  2. Nausea/Vomiting

    A common side effect of surgery and anesthesia defined as any nausea, retching, or vomiting that happens within the first 24 to 48 hours after a procedure

    Time frame: From the end of the surgical procedure and for up to 24 hours

07

Study locations

1 site
  • "Dr. Salvador Zubirán Anchondo" General Hospital
    Chihuahua City, Chihuahua 31100, Mexico
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07871617
Lead sponsor
Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo
Responsible party
Carlos R. Cervantes Sanchez, MD, MSc (General Surgery Service, Hospital General de Chihuahua - Dr. Salvador Zubirán Anchondo) — Principal investigator
First posted
Oct 13, 2026
Start date
Aug 1, 2025
Primary completion
Oct 31, 2025
Completion
Nov 14, 2025
Last update
Oct 13, 2026

Study contacts

Rubén Cuevas-Martínez, MD, MSc
study chair · "Dr. Salvador Zubirán Anchondo" General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion